Effect of IDX on COVID-19 infection
Funding or Partner Organisation: Noxopharm Limited
Start year: 2021
Summary: This project is to investigate the anti-inflammatory potential of IDX in Prof. Hansbro’s mouse model of SARS-CoV-2 induced hyperinflammation, and confirm the protective activity of IDX against COVID-19. The aim is to provide direct evidence with appropriate control cohorts of the anti-inflammatory effect of IDX in the context of SARS-CoV-2 infection, to support further clinical trials in the USA and Europe.
FOR Codes: Respiratory diseases , Respiratory System and Diseases (incl. Asthma), Infectious Diseases, Clinical health